Abstract |
A major challenge in cancer vaccine therapy is the efficient delivery of antigens and adjuvants to stimulate a controlled yet robust tumour-specific T-cell response. Here, we describe a structurally well defined DNA nanodevice vaccine generated by precisely assembling two types of molecular adjuvants and an antigen peptide within the inner cavity of a tubular DNA nanostructure that can be activated in the subcellular environment to trigger T-cell activation and cancer cytotoxicity. The integration of low pH-responsive DNA 'locking strands' outside the nanostructures enables the opening of the vaccine in lysosomes in antigen-presenting cells, exposing adjuvants and antigens to activate a strong immune response. The DNA nanodevice vaccine elicited a potent antigen-specific T-cell response, with subsequent tumour regression in mouse cancer models. Nanodevice vaccination generated long-term T-cell responses that potently protected the mice against tumour rechallenge.
|
Authors | Shaoli Liu, Qiao Jiang, Xiao Zhao, Ruifang Zhao, Yuanning Wang, Yiming Wang, Jianbing Liu, Yingxu Shang, Shuai Zhao, Tiantian Wu, Yinlong Zhang, Guangjun Nie, Baoquan Ding |
Journal | Nature materials
(Nat Mater)
Vol. 20
Issue 3
Pg. 421-430
(03 2021)
ISSN: 1476-4660 [Electronic] England |
PMID | 32895504
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adjuvants, Immunologic
- Cancer Vaccines
- Vaccines, DNA
|
Topics |
- Adjuvants, Immunologic
(administration & dosage)
- Animals
- Antigen Presentation
- Bacteriophage M13
(genetics)
- Cancer Vaccines
(administration & dosage, genetics, immunology)
- Cytotoxicity Tests, Immunologic
- Dendritic Cells
(drug effects, immunology)
- Hydrogen-Ion Concentration
- Immunotherapy
(methods)
- Lymphatic Metastasis
(prevention & control)
- Lymphocytes, Tumor-Infiltrating
(drug effects, immunology)
- Melanoma, Experimental
(immunology, pathology, therapy)
- Mice, Inbred C57BL
- Vaccines, DNA
(administration & dosage, genetics, immunology)
- Mice
|